Adial Pharmaceuticals Announces Planned Appointment of Celia Economides as Chief Financial Officer
Globe Newswire•26/10/2026•08:00 ET
0
Key Highlights
- ➤Celia Economides expected to become CFO after reconvened 2026 annual meeting approvals
- ➤Economides has helped execute more than $1 billion in biotech financings and strategic transactions
- ➤Adial expects name change to Azora Therapeutics and ticker change to AZR pending approvals
- ➤AT177 Phase 1 clinical trial planned for first half of 2027
Expert Statements
Matt Davidson, Ph.D., Adial Chief Development Officer and expected President and Chief Executive Officer
“Celia has raised capital in strong and challenging markets, built finance and investor relations functions from the ground up, and knows the autoimmune space well from her work at Aurinia and Kezar”
Matt Davidson, Ph.D., Adial Chief Development Officer and expected President and Chief Executive Officer
“We believe that combination is exactly what we need as we rapidly advance AT177 toward the clinic and build the organization for its next stage of growth.”
Celia Economides, Adial Executive Vice President of Finance and expected Chief Financial Officer
“I am excited to step into the Chief Financial Officer role during this important moment for the company”
Celia Economides, Adial Executive Vice President of Finance and expected Chief Financial Officer
“AT177’s targeted approach to AhR activation has the potential to address significant unmet needs for patients with ulcerative colitis, and I look forward to working with the team to support its continued development.”
Seasoned public company CFO with deep autoimmune disease experience has helped raise more than $1 billion over a 20+ year biotech career
Will lead the Company’s finance organization and capital strategy as it transitions to Azora Therapeutics and advances AT177 toward the clinic
Get started
Create a free account to read the full story.